Digestive Diseases and Sciences

, Volume 52, Issue 9, pp 2054–2062

Alleviation of Experimental Ulcerative Colitis with the Synthetic Peptide, F2A4-K-NS (Fibratide)

  • Xinhua Lin
  • Paul O. Zamora
  • Kazu Takahashi
  • Yi Lui
Original Article

Abstract

Recombinant fibroblast growth factors (FGFs) maintain the integrity of the gut epithelium and reduce mucosal injury in experimental inflammatory bowel disease (IBD). Chemically synthesized FGF mimetics could potentially extend the utility of FGFs by tailoring them for optimal bioactivity and oral administration, for example. Here, F2A4-K-NS (Fibratide), a synthetic FGF mimetic peptide, alleviated dextran sulfate sodium (DSS)-induced ulcerative colitis in mice when delivered systemically and, to a lesser extent, orally. Intraperitoneal injection of Fibratide (1 or 5 mg/kg/day) ameliorated DSS-induced ulcerative colitis, resulting in reduced weight loss, decreased colon wall thickening, and increased colon length. Fibratide also improved epithelial integrity by reducing histological-detectable crypt damage and inflammation. Orally administered Fibratide (1 mg/kg/day) was also effective in ameliorating symptoms with effects generally similar to those of intraperitoneal injection. In vitro studies were conducted to help clarify how Fibratide might act in vivo. Fibratide exhibited a modest enhancement of epithelial cell proliferation. On the other hand, Fibratide doubled the rate of epithelial cells migration and restitution in a cell culture model of wound repair. Collectively, the results indicate that Fibratide reduced the severity of experimental ulcerative colitis and may be potentially useful in the treatment of IBD.

Keywords

Mimetic peptide Ulcerative colitis Growth factor Epithelial Oral delivery 

References

  1. 1.
    Rutgeerts P, Vermeire S (2006) Review article:infliximab therapy for inflammatory bowel disease—seven years on. Aliment Pharmacol Ther 23:451–463PubMedCrossRefGoogle Scholar
  2. 2.
    Hull MA, Cullen DJ, Hudson N, Hawkey CJ (1995) Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration. Gut 37:610–612PubMedGoogle Scholar
  3. 3.
    Kusstatscher S, Sandor Z, Szabo S, Seddon A, Bohlen P (1995) Different molecular forms of basic fibroblast growth factor (bFGF) accelerate duodenal ulcer healing in rats. J Pharmacol Exp Ther 275:456–461PubMedGoogle Scholar
  4. 4.
    Satoh H, Asano S, Maeda R, Murakami I, Inada I, Sato F, Shino A (1997) Prevention of gastric ulcer relapse induced by indomethacin in rats by a mutein of basic fibroblast growth factor. Jpn J Pharmacol 73:229–241PubMedGoogle Scholar
  5. 5.
    Satoh H, Shino A, Sato F, Asano S, Murakami I, Inatomi N, Nagaya H, Kato K, Szabo S, Folkman J (1997) Role of endogenous basic fibroblast growth factor in the healing of gastric ulcers in rats. Jpn J Pharmacol 73:59–71PubMedGoogle Scholar
  6. 6.
    Szabo S, Folkman J, Vattay P, Morales RE, Pinkus GS, Kato K (1994) Accelerated healing of duodenal ulcers by oral administration of a mutein of basic fibroblast growth factor in rats. Gastroenterology 106:1106–1111PubMedGoogle Scholar
  7. 7.
    Howarth GS, Xian CJ, Read LC (1998) Insulin-like growth factor-I partially attenuates colonic damage in rats with experimental colitis induced by oral dextran sulphate sodium. Scand J Gastroenterol 33:180–190PubMedCrossRefGoogle Scholar
  8. 8.
    Jeffers M, McDonald WF, Chillakuru RA, Yang M, Nakase H, Deegler LL, Sylander ED, Rittman B, Bendele A, Sartor RB, Lichenstein HS (2002) A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 123:1151–1162PubMedCrossRefGoogle Scholar
  9. 9.
    Matsuura M, Okazaki K, Nishio A, Nakase H, Tamaki H, Uchida K, Nishi T, Asada M, Kawasaki K, Fukui T, Yoshizawa H, Ohashi S, Inoue S, Kawanami C, Hiai H, Tabata Y, Chiba T (2005) Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology 128:975–986PubMedCrossRefGoogle Scholar
  10. 10.
    Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ (2003) Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349:350–357PubMedCrossRefGoogle Scholar
  11. 11.
    Zeeh JM, Procaccino F, Hoffmann P, Aukerman SL, McRoberts JA, Soltani S, Pierce GF, Lakshmanan J, Lacey D, Eysselein VE (1996) Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 110:1077–1083PubMedCrossRefGoogle Scholar
  12. 12.
    Beck PL, Podolsky DK (1999) Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 5:44–60PubMedCrossRefGoogle Scholar
  13. 13.
    Finch PW, Cheng AL (1999) Analysis of the cellular basis of keratinocyte growth factor overexpression in inflammatory bowel disease. Gut 45:848–855PubMedCrossRefGoogle Scholar
  14. 14.
    Finch PW, Pricolo V, Wu A, Finkelstein SD (1996) Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease. Gastroenterology 110:441–451PubMedCrossRefGoogle Scholar
  15. 15.
    Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K (2001) VEGF, basic-FGF, TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 96:822–828PubMedGoogle Scholar
  16. 16.
    Lin X, Takahashi K, Campion SL, Liu Y, Gustavsen GG, Pena LA, Zamora PO (2006) Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo International. J Mol Med 17:833–841Google Scholar
  17. 17.
    Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK (2001) Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 120:925–937PubMedCrossRefGoogle Scholar
  18. 18.
    Ciacci C, Lind SE, Podolsky DK (1993) Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastroenterology 105:93–101PubMedGoogle Scholar
  19. 19.
    Arakawa T, Wen J, Philo JS (1993) Densimetric determination of equilibrium binding of sucrose octasulfate with basic fibroblast growth factor. J Protein Chem 12:689–693PubMedCrossRefGoogle Scholar
  20. 20.
    Volkin DB, Verticelli AM, Marfia KE, Burke CJ, Mach H, Middaugh CR (1993) Sucralfate and soluble sucrose octasulfate bind and stabilize acidic fibroblast growth factor. Biochim Biophys Acta 1203:18–26PubMedGoogle Scholar
  21. 21.
    Maj JG, Paris F, Haimovitz-Friedman A, Venkatraman E, Kolesnick R, Fuks Z (2003) Microvascular function regulates intestinal crypt response to radiation. Cancer Res 63:4338–4341PubMedGoogle Scholar
  22. 22.
    Okunieff P, Mester M, Wang J, Maddox T, Gong X, Tang D, Coffee M, Ding I (1998) In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat Res 150:204–211PubMedCrossRefGoogle Scholar
  23. 23.
    Alvarez E, Fey EG, Valax P, Yim Z, Peterson JD, Mesri M, Jeffers M, Dindinger M, Twomlow N, Ghatpande A, LaRochelle WJ, Sonis ST, Lichenstein HS (2003) Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 9:3454–3461PubMedGoogle Scholar
  24. 24.
    Dorr W, Reichel S, Spekl K (2005) Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol 75:99–105PubMedCrossRefGoogle Scholar
  25. 25.
    Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL (1998) Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58:933–939PubMedGoogle Scholar
  26. 26.
    Farrell CL, Rex KL, Chen JN, Bready JV, DiPalma CR, Kaufman SA, Rattan A, Scully S, Lacey DL (2002) The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 35 (Suppl 1):78–85PubMedCrossRefGoogle Scholar
  27. 27.
    Miceli R, Hubert M, Santiago G, Yao DL, Coleman TA, Huddleston KA, Connolly K (1999) Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exp Ther 290:464–471PubMedGoogle Scholar
  28. 28.
    Dignass AU, Tsunekawa S, Podolsky DK (1994) Fibroblast growth factors modulate intestinal epithelial cell growth and migration. Gastroenterology 106:1254–1262PubMedGoogle Scholar
  29. 29.
    Houchen CW, George RJ, Sturmoski MA, Cohn SM (1999) FGF-2 enhances intestinal stem cell survival and its expression is induced after radiation injury. Am J Physiol 276:G249–G258PubMedGoogle Scholar
  30. 30.
    Boismenu R, Chen Y, Chou K, El-Sheikh A, Buelow R (2002) Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Ann Rheum Dis 61 (Suppl 2):ii19–ii24PubMedGoogle Scholar
  31. 31.
    Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, Tesi RJ (2005) RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 11:713–719PubMedCrossRefGoogle Scholar
  32. 32.
    Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M (2006) Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut (in press)Google Scholar
  33. 33.
    Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M (2006) Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci USA 103:4228–4233PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Xinhua Lin
    • 1
  • Paul O. Zamora
    • 1
  • Kazu Takahashi
    • 1
  • Yi Lui
    • 1
  1. 1.BioSurface Engineering TechnologiesInc., 9430 Key West Avenue, Suite 220RockvilleUSA

Personalised recommendations